Table 1.

Patient demographics and baseline characteristics

CharacteristicCorticosteroid prophylaxis (n = 40)No corticosteroid prophylaxis (n = 73)
Age in years, median (range)60 (49–83)62 (38–81)
Race, n (%)
 White34 (85.0)66 (90.4)
 Black or African American1 (2.5)2 (2.7)
 Asian3 (7.5)2 (2.7)
 American Indian or Alaskan native0 (0.0)2 (2.7)
 Not reported2 (5.0)1 (1.4)
Primary cancer diagnosis, n (%)
 Epithelial ovarian cancer34 (85.0)67 (91.8)
 Fallopian tube cancer3 (7.5)5 (6.8)
 Primary peritoneal cancer3 (7.5)1 (1.4)
Histology, n (%)
 Serous36 (90.0)67 (91.8)
 Endometrioid2 (5.0)1 (1.4)
 Mixed2 (5.0)2 (2.7)
 Carcinosarcoma0 (0.0)2 (2.7)
 Mullerian carcinoma0 (0.0)1 (1.4)
ECOG PS, n (%)
 020 (50.0)32 (43.8)
 120 (50.0)41 (56.2)
Platinum resistance, n (%)
 Yes31 (77.5)65 (89.0)
 No9 (22.5)8 (11.0)
Number of prior systemic therapies, n (%)
 1–21a (2.5)16 (22)
 3–439 (97.5)30 (41)
 5+0 (0)27 (37)
Prior compound exposure, n (%)
 Platinum40 (100.0)73 (100.0)
 Taxane40 (100.0)73 (100.0)
 Bevacizumab24 (60.0)53 (72.6)
 PARP inhibitor8 (20.0)15 (20.5)
  • Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.

  • aOne patient enrolled with two prior lines of therapy, although three or four prior lines were defined in the protocol.